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6/j.bAutologous stem cell transplant as primary (first ASCT) therapy in multiple myeloma (MM) is standard prac-
tice. The role of a second ASCTas management of relapsed disease remains uncertain. We conducted a ret-
rospective case-matched control analysis on patients (n 5 106) who underwent a second ASCT compared
with conventional chemotherapy (CCT) as for relapsed MM. The median age was 53 years (range: 26-75) and
median follow-up 48 months (range: 8, 136). The cumulative incidence of 1 and 5 years nonrelapse mortality
(NRM) was 7% (95% confidence interval [CI] 3%-13%) and 12% (95% CI 7%-19%), with a second ASCT in-
ducing a greater partial remission (PR) rate of 63%. The 4-year overall survival (OS) rate was 33% (95% CI
24%-45%). Factors associated with improved OS and progression-free survival (PFS) included younger age
(\55 years), b2MG\2.5 mg/L at diagnosis, a remission duration of.9months from first ASCT, and a greater
PR in response to their first ASCT. In a matched-cohort analysis with patients receiving conventional chemo-
therapy (CCT), the same factors were associated with improved OS, with the exception of a longer remis-
sion duration (.18 months) from first ASCT. Second ASCT in relapsed MM is associated with superior OS
and PFS compared with CCT, offering a potential consolidative option for selected patients.
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Multiple myeloma (MM) remains an incurable
plasmacell tumor for themajorityofpatients. Itsmedian
age of presentation is 70 years [1]. For younger patients
withMM, the standard of care is induction therapy con-
solidated with high-dose melphalan (HDM) and autol-
ogous peripheral blood stem cell (ASCT) rescue [2-4].
Studies to date clearly demonstrated that patients who
receive ASCT as part of their initial management will
have an increased event-free survival (EFS) and overall
survival (OS), compared with those receiving conven-
tional chemotherapy (CCT) [4-6]. Almost all patients
with MM will relapse at some stage following initial
therapy—the majority within 3 years of an ASCT.
However, the prognosis and optimal therapy for
patients relapsing after this initial intensive therapeutic
approach is less certain. The recent introduction of
novel agents such as Thalidomide, Lenalidomide, and
Bortezomib has resulted in effective disease responses,
and although the durability of such responses remain
to be tested, their use is associated with an improved
Biol Blood Marrow Transplant 17:1638-1645, 2011 1639ASCTas Salvage Therapy in Myelomasurvival [7-9]. Nonetheless, many questions about
management of relapsed disease remain.
One clinical treatment option in the management
of relapsed disease is a second ASCT. The first report
of the use of ASCT as salvage therapy demonstrated
a significantly prolonged survival compared with stan-
dard therapy [10]. Favorable prognostic variables in
these patients were an initial remission of.12 months
and a low b2m (#2.5 mg/L) at diagnosis. More re-
cently, a retrospective study of 26 patients who under-
went a second ASCT as salvage therapy demonstrated
a trend in improved OS and EFS, a though 2 similar
single institutional studies were unable to definitively
demonstrate the true efficacy of such a strategy
[11-13]. To date, there have been no randomized
controlled clinical studies performed to examine the
role of a second ASCT in relapsed disease, and
importantly identifying factors that may delineate
which patients may benefit more from a second
ASCT. Therefore, we report the results of a case-
matched retrospective study examining the role of
a second ASCT in the management of relapsed disease
following a previous ASCT, identifying factors associ-
ated with disease-free (DFS) and OS.PATIENTS AND METHODS
Eligible patients were identified from the British So-
ciety for Blood and Marrow Transplantation (BSBMT)
DataRegistry andadditional patient-specificdatawasac-
quired directly from individual centers. Consent for data
to be registered on the BSBMTRegistry for use in activ-
ity, outcome, and research analysis was obtained at the
time of transplantation, in line with European Bone
Marrow Transplant Registry directives. This study was
approved and registered by the BSBMT Clinical Trials
Committee. Patients undergoing multiple ASCT as
part of a tandem programwere excluded. From a cohort
of patients who underwent a first ASCT between 1990
and2002, therewere 312ASCT in149patients, ofwhich
11 were third transplants and 1 a fourth, with 1 patient
having no available data and therefore 15 were excluded.
Thus, the study cohort consisted of 296 first and
second transplant pairs performed in 148 patients.
Identification of Controls for Case-Control
Analysis
An appropriate control group was identified using
the following criteria: gender, age at first transplanta-
tion, b2 microglobulin (b2MG) at diagnosis, duration
of first remission (whether complete or partial), status
at first transplantation, year of first transplantation,
total body irridiation (TBI)-containing conditioning
regimen, time fromdiagnosis to first transplantation, re-
sponse to first transplantation, immunoglobulin isotype,
and disease stage at diagnosis. Of these factors, age atfirst transplantation, year of first transplantation, and
b2MG at diagnosis were independently statistically sig-
nificant by Cox regression for OS. Data for b2MG at di-
agnosis were available for only 72 of the 148 patients
(49%).Thus, controlswerematchedonage atfirst trans-
plantation, status at first transplantation, and length of
remission after first transplantation (.9/ 24months).
It was also decided to match for year of transplantation
(in 4-year intervals) to account for procedural and sup-
portive care changes.
All first transplantations performed in the same time
interval were then identified from the BSBMTRegistry.
The BSBMT Registry identified 2896 HDM/ASCT
performed for MM in this interval, of which 505 were
multiple transplantations (either tandem or second
transplantations on relapse), leaving 2391 single
ASCT.Of these, 1578 had complete data on all the vari-
ables required for matching described above. Finally,
525 of these had relapsed after the first transplantation,
and in 342 of these we had complete data concerning
the relapse, including adequate follow-up after relapse.
Thus, the case-matched control cohort was selected
from these 342 patients. From the initial study cohort
of the 148 patients who had second ASCT, 106 were
matchedon all the criteriawith106patientswhohad sin-
gle ASCT in the control group, thus completing the
study case-matched cohorts for analysis.
Statistical Analysis
Theoriginal 2 cohorts of patientswere comparedus-
ing Fisher exact test for categoric data and theWilcoxon
test for continuous data. Overall progression-free sur-
vivals (PFSs) were calculated by Kaplan-Meier, and uni-
variate comparisons were made within the second
transplant group by the log-rank test for binary or cate-
goric variables and by Cox proportional hazard regres-
sion for continuous and ordered categoric variables
and for multivariable analyses. These analyses identified
the prognostic factors in the cohort. The 2 cohorts (all
148 second transplantations and all 342 single transplan-
tation patients) were compared using stratified Cox re-
gression, stratifying on the prognostic factors identified
in the preliminary analysis described above. Matching
patients were selected from the single transplantation
group to match as many as possible of the second trans-
plantation cohort on all the prognostic factors, giving 2
case-matchedcohortsof n5 106patients each.Compar-
isons between these 2 groups were made using theWil-
coxon matched-pairs test for categoric variables and the
stratified Cox regression for the survival variables.RESULTS
Patient Characteristics
The patient and disease-specific characteristics are
illustrated in Table 1. For patients undergoing
Table 1. Patient Characteristics by Treatment at Relapse
Year
All Patients Case-matched Control P P
Second ASCT CCT Second ASCT CCT All Case-Matched
n 148 342 106 106
Median age at diagnosis (years; range) 52 (25, 72) 53 (25, 70) 53 (25, 72) 53 (25, 70) .037 .843
Median age at first ASCT (years; range) 53 (26, 75) 55 (25, 76) 54 (26, 75) 54 (25, 76) .019 .413
Sex: female/male (%) 45/103 (30%/70%) 111/219 (34%/66%) 33/73 (31%/69%) 35/66 (35%/65%) .500 .590
14 u/k 5 u/k
Disease subtype: 51 u/k 13 u/k .418 .851
IgG 84 (57%) 161 (55%) 60 (57%) 55 (59%)
IgA 30 (20%) 77 (26%) 23 (22%) 22 (24%)
Light chain disease 28 (19%) 42 (14%) 21 (20%) 14 (15%)
Other 6 (4%) 11 (4%) 2 (2%) 2 (2%)
b2 microglobulin at diagnosis
(median mg/L; range)
76 u/k 290 u/k 51 u/k 89 u/k .948 .848
4 (0.4-48.6) 3.75 (0-40) 4.3 (0.4, 48.6) 4.1 (0, 11.1)
Stage at diagnosis (Durie/Salmon) 15 u/k 162 u/k 6 u/k 54 u/k .167 .452
I 23 (17%) 32 (18%) 15 (15%) 9 (17%)
II 28 (21%) 54 (30%) 21 (21%) 15 (29%)
III 82 (62%) 94 (52%) 64 (64%) 28 (54%)
Time to first ASCT (range) months: 7 (3, 146) 8 (1, 125) 6 (3, 141) 9 (4, 100) .006 .004
<6 mns 55 (37%) 78 (23%) 46 (43%) 23 (23%)
6-12 mns 56 (38%) 148 (44%) 38 (36%) 43 (43%)
>12 mns 37 (25%) 109 (33%) 22 (21%) 35 (35%)
Length of remission post-first ASCT: .001 .317
<12 mns 35 (24%) 148 (43%) 38 (36%) 33 (31%) (excluding
>24 mns category-
matching criterion)
12-18 mns 17 (11%) 61 (18%) 16 (15%) 14 (13%)
18-24 mns 19 (13%) 46 (13%) 10 (9%) 17 (16%)
>24 mns 87 (52%) 87 (25%) 42 (40) 42 (40%)
Status at first ASCT: 6 u/k .303 -
CR 20 (14%) 64 (19%) 16 (15%) 16 (15%) (matching
criterion)PR 91 (64%) 222 (65%) 75 (71%) 75 (71%)
MR 10 (7%) 11 (3%) 2 (2%) 2 (2%)
SD 5 (4%) 10 (3%) 3 (3%) 3 (3%)
PD 16 (11%) 35 (10%) 10 (9%) 10 (9%)
Year of first ASCT: .001 -
1990-1993 23 (16%) 73 (21%) 15 (14%) 15 (14%) (matching
criterion)1994-1997 75 (51%) 107 (31%) 45 (42%) 45 (42%)
1998-2002 50 (34%) 162 (47%) 46 (43%) 46 (43%)
u/k indicates unknown; mns, months; ASCT, autologous stem cell transplant; CCT, conventional chemotherapy; PD, progressive disease; SD, stable dis-
ease; MR, minimal response; CR, complete remission; PR, partial remission.
1640 Biol Blood Marrow Transplant 17:1638-1645, 2011G. Cook et al.a second ASCT, the median age of the cohort overall
and those selected for the case-matched analysis was
53 years (range: 26-75) and 54 years (range: 26-75), re-
spectively. In patients who underwent a second ASCT,
the median interval between diagnosis and first ASCT
was 6 months (range: 3-141). For those who received
CCT as salvage therapy, themedian time from diagno-
sis to first ASCT was 9 months (range: 4-100). No sig-
nificant difference in the time to relapse from first
ASCT was demonstrated between the second ASCT
and CCT cohorts (median 19 months [range: 3-106]
vs 18 months [range: 4-80]; P 5 .410). In the second
ASCT group, the use of TBI in the conditioning of
the first ASCT did not affect the time to relapse: TBI
(n 5 11) means 17 months (95% confidence interval
[CI] 11, 33) versus no TBI (n5 133), mean 25 months
(95% CI 20, 30), P5 .31 (Mann-Whitney test).Nonrelapse Mortality (NRM)
At a median follow-up of 108 months (range:
8-174) for those who underwent a second ASCT assalvage therapy, 21 of 143 evaluable patients died of
treatment-related causes. The 100-day NRM cumula-
tive incidence for the total second ASCT (n5 148) and
ASCT cohort used in the case-matched analysis (n 5
106) were 8% (95% CI 4%-13%) and 7% (3%-
14%). The cumulative incidence of NRM at 1 and 5
years for the second ASCT cohort was 7% (95% CI
3%-13%) and 12% (95% CI 7%-19%), respectively
(P \ .0001, Supplementary Figure 1). No factors
were identified as associated with theNRM in a univar-
iate. No treatment-related deaths were reported in the
CCT cohort.Response Rate, Durability of Response, and
Survival
A complete remission (CR) rate of 26% (95% CI
19, 33) and partial remission (PR) rate of 37% (95%
CI 29, 44) were reported in the total second ASCT co-
hort (n5 148), compared with a CR rate of 27% (95%
CI 19, 36) and PR rate of 37% (95% CI 27, 45) in the
case-matched analysis cohort (n 5 106; total second
Figure 1. Cumulative incidence of NRM (Supplementary Figure 1) and
overall survival for patients undergoing a second ASCTor CCT for re-
lapsed MM.
Biol Blood Marrow Transplant 17:1638-1645, 2011 1641ASCTas Salvage Therapy in MyelomaASCT vs matching cohort, P 5 .66) for the difference
between the matched subset and the rest of the second
transplantation group. In the case-matched cohort
analysis, 182 patients have died (second ASCT n 5
91, CCT n5 91), with a median time from first trans-
plantation to death of 37 months for the second ASCT
cohort and 13 months for the CCT cohort. The ma-
jority of patients died because of disease progression
(n 5 116), although 14 died of nonmyeloma-related
causes. As such, there was a significant difference in
the NRM between the second ASCT and CCT co-
horts (P 5 .001). Thus, the 4-year relapse-associated
mortality rate for the second ASCT cohort was 68%
compared with 78% for the CCT cohort (P 5
.0001). The 4-year OS for those who underwent a sec-
ond ASCT was 32% (95% CI 24%-45%) compared
with 22% (95% CI 13%-35%) for those who under-
went CCT alone at relapse (P\ .0001; Figure 1B).Figure 2. The effect of age at first ASCTon the overall survival from
relapse in patients undergoing either a second ASCT or CCT (n 5
106) as salvage therapy for relapsed MM. Patients age#54 years at first
ASCTwho received a second ASCTor CCTat relapse and those age 55
to 65 years and .65 years at first ASCT (Supplementary Figure 2).Parameters Influencing Survival Post-Salvage
Therapy
Patient’s age at first transplant predicts survival
from relapse
Univariate analysis demonstrates that OS and PFS
from first and second ASCT is superior in patients age
\65 years at the time of their first ASCT, with a me-
dian OS from the second ASCT of 3.2 years (95%
CI 2.4, 3.9) for those #54 years of age at first ASCT,
2.0 years (95% CI 1.4, 2.6) for those 55-65, and 0.8
years (95% CI 0.1, 1.9) for those .65 (P\ .0001).
For the comparative analysis, we examined the OS
from relapse in each cohort. The median OS from re-
lapse for patients age #54 years at first ASCT was 3.5
years (95%CI 2.7,4.6) in the second ASCT cohort and
1.75 years (95% CI 1.1, 2.1) in the CCT cohort, as il-lustrated in Figure 2A (P5 .0019). In contrast, for pa-
tients age 55 to 65 years at first ASCT, the median OS
was 2.7 years (95% CI 2.2, 3.4) in the second ASCT
cohort and 1 year (95% CI 0.2,2.7) in the CCT cohort
(P 5 .0015), with a median OS from relapse of 1.1
years (95% CI 0.1,3.4) and 0.7 years (95% CI
0.2,2.7) in the second ASCT and CCT cohorts, re-
spectively, for those age .65 years at first ASCT (P
5 .92; Supplementary Figure 2).
b2MG at diagnosis predicts survival from relapse
The level of b2MG at diagnosis has previously
been demonstrated to be a significant prognostic fac-
tor [14]. Therefore, we examined whether b2MG at di-
agnosis could differentiate those who may perform
better from a second ASCT as salvage therapy com-
pared with CCT. A b2MG\2.5 mg/L is associated
with OS advantage whether a second ASCT or CCT
is utilized as salvage therapy (Supplementary
Figure 3), although no effect on PFS is demonstrated.
However, this may be related to the lack of availability
of b2MG in more than half the study population.
Survival by duration of remission post-first
transplant
It has been shown in previous studies that the du-
ration of response to a first ASCT may predict for re-
sponse to subsequent therapy, whether it be a second
ASCT or CCT [13,15]. In a time-dependent regres-
sion analysis, the duration of first remission signifi-
cantly affects the PFS (P 5 .019 for remission \ 9
months, P 5 .0006 for remission .18 months;
Figure 3A). Similarly, the time from first ASCT to
Figure 3. Time-dependent regression analysis of the effect of duration
of response from first ASCT on PFS (A) and OS (Supplementary
Figure 4) post-first ASCT and the effect of duration of response from
first ASCT of .18 months on OS compared with CCT
(Supplementary Figure 5).
Figure 5. The combined effect of age at second ASCT and remission
duration from first ASCTon 5-year OS.
1642 Biol Blood Marrow Transplant 17:1638-1645, 2011G. Cook et al.relapse significantly affected OS, becoming significant
after 9months post-ASCT (P5 .001) and increasing in
significance beyond 18 months post-first ASCT (P\
.0002; Supplementary Figure 4). When a second
ASCT was compared with CCT as salvage therapy,
a duration of response greater than 18 months post-
first ASCT demonstrated a superior OS in patients re-
ceiving a second ASCT compared with CCT, with
a median of 3.9 years (95% CI 3.1,4.8) versus 1.8 years
(95% CI 1.1,2.3) (P 5 .0011), respectively
(Supplementary Figure 5).Figure 4. The effect of depth of response following a first ASCTon OS
following salvage therapy for progressive disease: patients achieving
a CR/PR, treated by second ASCTor CCT.Survival by disease status following an initial
ASCT
The depth of response has been shown to predict
improvedPFS andOS, although the timingof such a re-
sponse remains in debate [16-18]. We determined
whether the depth of response following a first ASCT
significantly affected the OS from relapse differentially
in each treatment cohort (second ASCT vs CCT). In
patients who achieved at least a PR (CR/PR) following
a first ASCT, a second ASCT as salvage therapy
demonstrated a superior OS (3.1 years [95% CI 2.5,
3.7] vs 1.1 years [95% CI 1.0, 1.8]; P \ .0001)
compared with those who received CCT (Figure 4).
However, in patients with poorly responding disease
to ASCT in first line, demonstrating no response, min-
imal response, or progressive disease, then no difference
in OS (2.0 years [95% CI 0.2, 3.1] vs 1.0 years [95% CI
0.4, 2.0];P5 .394)was demonstrable, although thismay
relate to low patient numbers (n5 15).Multivariate Analysis
To determine what parameters should be consid-
ered in treatment decision making for salvage therapy
and whether to incorporate a second ASCT, we per-
formed a multivariate regression analysis using the
case-matched control pairings, to examine the inde-
pendent influence of age at first ASCT, status at first
ASCT, length of remission post-first ASCT, and
year of transplantation (Supplementary Table 1).
The OS and PFS of patients after second ASCT is sig-
nificantly affected by the patient’s age at second ASCT
and the remission duration from first ASCT with
b2MG at diagnosis affecting OS only. We wished to
provide a clinically relevant scoring system to assist
Biol Blood Marrow Transplant 17:1638-1645, 2011 1643ASCTas Salvage Therapy in Myelomain decisionmaking, and we examined the 5-year OS for
patients score 0 ($65 years, remission #24 months: n
5 10), 1 (#65 years or remission$24 months: n5 65)
and 2 (#65 years and remission$24 months: n5 72).
The 5-year OS for score 0, 1, and 2 was 0%, 14%, and
43%, respectively (P 5 .001; Figure 5).DISCUSSION
High-dose Melphalan supported by ASCT in first
remission is currently accepted as gold standard consol-
idation for patients with MM deemed fit as first-line
therapy. However, prolonged progression free survival
post-ASCT is uncommon, and selection of optimal
treatment for disease relapse is the major decision for
patients and treating clinicians [12,13]. The role of
planned second ASCT as initial therapy in MM has
been studied prospectively in randomized trials and
analysis from large registry studies [16,19,20]. A
second, on-demand ASCT has been reported to be ef-
ficacious in patients with malignant lymphoma and
Hodgkin’s disease, associated with limited NRM and
a PFS of 30% to 40% [21-23]. In the setting of
relapsed MM, clinicians have opted for a second
ASCT following reinduction therapy, but randomized
controlled trial data or systematic outcome analysis in
this setting is lacking [24,25]. As such, there is a lack
of clear guidance and criteria for selection of patients
who may benefit from this approach.
We present the outcomes of the large cohort of pa-
tients who underwent a second ASCT as salvage man-
agement of their relapsed MM following an initial
ASCT with optimal follow-up, comparing these to
a case-matched cohort. A second ASCT demonstrated
superior relapse-associated mortality compared with
CCT (68% vs 78%), associated with an improved
OS (32% vs 22%) at 4 years. This compares favorably
with previously published small studies in this setting,
although these studies reported shorter follow-up
[24-26]. To identify prognostic factors, we addressed
key parameters that may influence the outcome of
a second ASCT at relapse, including age at first
transplantation, disease status at second ASCT, and
time to relapse following the first ASCT. When time
to relapse from the first ASCT is examined, the
significance starts to emerge at 9 months from the
first ASCT, although the significance increases with
increasing interval between first ASCT and relapse.
This finding is earlier than previous reports of
salvage ASCT and the impact of time to relapse on
survival where a significant benefit is reported at 12
to 18 months, and thus the data presented here
provides the treating clinician with evidence to assist
clinical decision making [26-29]. Age at second
transplantation and b2MG were both identified as
significant independent prognostic factors, affectingboth time to progression and OS. When taken
together, the data assists in clinical decision making,
indicating that those over the age of 65 with less than
a 2-year remission from the first ASCT benefit the
least from a second ASCT and should be considered
for alternative consolidation strategies.
It is important to recognize the limitations of this
retrospective study. First, the reinduction regimens,
both pre-ASCTand in theCCTcohort,wereheteroge-
neous, although, using defined response criteria, it was
suitable to analyze and compare the study cohorts. Sec-
ond, therewere insufficient data on cytogenetic analysis
and b2MG at diagnosis and at relapse to permit confi-
dence in a comparative analysis. These issues will be ad-
dressed in a UK randomized prospective study (NCRI
Myeloma X study), which is currently recruiting.
Although the safety of a first ASCT has improved
over recent years, concerns regarding the use of a second
ASCT as salvage therapy may be raised, associating this
procedure with increased toxicity and NRM. We dem-
onstrated that the NRM was 7% (95% CI 3%-13%)
and 12% (95% CI 7%-19%) at 1 and 5 years, similar
to that reported in smaller studies [24,25]. However, it
has been suggested that such patients may have
a higher frequency of grade 3 and 4 toxicities including
renal dysfunction [25].
In recent years novel agents such as Bortezomib,
Thalidomide, and Lenalidomide have been introduced
both for up-front and salvage therapy in MM [30].
Such therapies, in combination, have significantly in-
creased the response rates of relapsed MM. Although
the depth and rapidity of responses to Bortezomib-
containing regimens are significant, with response rates
in the range of 60% to 70%, the duration of responses
remains disappointing in the salvage setting [31,32].
This has led several investigators to study the role of
new drug combinations including Bortezomib and
other, novel agents [33,34]. An alternative strategy is to
use a second ASCT, shown here to have superiority
over CCT in terms of PFS and OS, to augment the
responses to novel agents. This is the strategy behind
the current UK RCT in this setting where
a Bortezomib combination as reinduction therapy is
consolidated either with a low-dose alkylating regimen
or a second ASCT, in progress (http://www.ukmf.
org.uk/trials.htm).
Despite the recent advances in the treatment of
MM, a second ASCT as salvage therapy could poten-
tially add to the benefit of novel therapies in eligible
patients. Although randomized control trial–derived
data is lacking in this setting, the retrospective registry
data analysis presented here can be employed to guide
clinicians and patients to their therapeutic decisions
incorporating a second ASCT for the treatment of re-
lapsed disease. In summary, the data presented here of-
fers clinically useful conclusions regarding the role and
value of a second ASCT as salvage therapy for relapsed
1644 Biol Blood Marrow Transplant 17:1638-1645, 2011G. Cook et al.MM.The availability of novel agents may improve fur-
ther the disease responsiveness to a second ASCT
rather than negate its usefulness in the salvage setting,
by improving the depth of response pre-ASCT, which
may result in improved durability of responses.ACKNOWLEDGMENTS
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